Creo Medical Group (LSE:CREO), the medical device company quoted on the FTSE AIM All Share Index, has set out a sharp improvement in sales and a narrower loss in its first half. Unaudited interim results published on 30 September 2026 showed Revenue up 45% to £3.2 million for the six months to 30 June, while the underlying operating loss was reduced by more than a quarter to £4.9 million. Management said it is confident of full-year revenue growth of 50% to 60%.

What the company does

Creo Medical develops devices used by clinicians in minimally invasive procedures. Its best-known product is the Speedboat device, which the company says has now been used in more than 10,000 procedures. It has also been commercialising its MicroBlate range, announcing in July 2026 that MicroBlate Flex had exceeded 100 clinical cases, and issuing a commercial update on MicroBlate Fine in May.

Latest developments

The first half was marked by a significant reshaping of the business. Creo raised £5.5 million through an share placing announced on 22 May 2026, and a further £2.0 million through a convertible Loan note. It disposed of its Manufacturing operations, and in May also proposed selling its remaining 49% interest in Creo Medical SL. The interim results said the company expects to reach an agreement on that sale in the fourth quarter of 2026.

Cost discipline has been a central theme. Underlying operating costs fell 15% to £7.9 million in the first half, according to the interim results. A trading update on 28 July had previously indicated revenue growth driven by commercial momentum and expansion into new regions. The company also appointed a new nominated adviser and corporate broker in June.

Financial and Dividend picture

Creo reported cash of £7.4 million at the end of June 2026 in its trading update. Although the loss is narrowing, the company is not yet profitable and does not pay a dividend. Management has said it is confident in its near-term funding position and its path to profitability, though the Business has relied on Share Capital and Debt fundraisings to support its development.

Sector and index context

Medical technology companies on AIM often face a long and capital-intensive journey from regulatory approval to widespread adoption. Clinicians and hospitals tend to adopt new devices gradually, and growth depends on training, reimbursement and evidence from clinical use. Within the FTSE AIM All Share Index, Creo is one of a number of healthcare technology names whose valuations are sensitive to funding news and commercial milestones.

Key risks

The most immediate risk is financial. With £7.4 million of cash at the half-year and an ongoing operating loss, the timing and terms of the Creo Medical SL sale matter for the group's runway. Any delay could increase pressure to raise further capital, which could dilute shareholders. Commercial risks include the pace of hospital adoption, competition from established device makers and the challenge of maintaining growth after outsourcing manufacturing.

What to watch next

The key near-term event is the expected agreement to sell the remaining 49% of Creo Medical SL in the fourth quarter of 2026. Investors will also watch whether the company meets its target of 50% to 60% revenue growth for the full year, and for further updates on Speedboat procedure numbers and MicroBlate adoption. A year-end trading update in early 2027 would give the next detailed read on progress towards profitability.